# A Phase3 Study to Evaluate the Efficacy and Safety of MEDI3250 in Healthy Japanese Children Age 7 Years Through 18 Years

> **NCT02269475** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 1369 (actual)

## Conditions studied

- Healthy Japanese Children Age 7 Years Through 18 Years

## Interventions

- **DRUG:** MEDI3250
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02269475
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10
- **Primary completion:** 2015-04
- **Final completion:** 2015-04
- **Target enrollment:** 1369 (ACTUAL)
- **Last updated:** 2017-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02269475

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02269475, "A Phase3 Study to Evaluate the Efficacy and Safety of MEDI3250 in Healthy Japanese Children Age 7 Years Through 18 Years". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02269475. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*